Hyperoside promotes osteoblast differentiation by increasing osteoclast-derived migrasomes to alleviate osteoporosis

Read full text Summarise with VIRAT
Authors: Shu Yan, Zhenguo Luo, Bingqin Ma, Jiajia Dou, Lvmei Liu, Lujie Miao
Cited by: 0
References: 50

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

OBJECTIVES: Osteoporosis, resulting from an imbalance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption, can be alleviated by hyperoside. Migrasomes, as newly discovered extracellular vesicles, play a crucial role in mediating intercellular communication. However, it remains unclear whether hyperoside alleviates osteoporosis by mediating intercellular communication between osteoblasts and osteoclasts through migrasomes. This study investigates the potential therapeutic mechanisms of hyperoside in treating osteoporosis using an ovariectomized mouse model. METHODS: Hyperoside was administered to the mice by intragastric gavage daily for 2 months. Micro-CT scans and histopathological analyses were performed to evaluate bone formation. Migrasomes derived from hyperoside-treated osteoclasts were characterized by transmission electron microscopy, Western blot, and immunofluorescence, and subsequently used to treat osteoblasts followed by RNA sequencing. RESULTS: Micro-CT scans and histopathological evaluations showed that hyperoside reduced bone resorption and osteoclast numbers in ovariectomized mice. Immunofluorescence staining revealed that hyperoside increased the expression of osteoblast regulators OPG and RUNX2. Hyperoside increased migrasome secretion from osteoclasts, which was validated by transmission electron microscopy and Western blot analyses. Migrasomes were then used to treat MC3T3-E1 cells, boosting osteoblast marker expressions and differentiation. RNA sequencing of migrasomes showed distinct regulatory patterns, with upregulated genes in the hyperoside-treated migrasomes compared to the control linked to immune responses, iron ion homeostasis, oxidative stress, and apoptosis, and downregulated genes related to lipid metabolism. Notably, hyperoside-regulated migrasomes also affected ferroptosis by increasing ferroptosis repressors Nr4a1, Lcn2, Nupr1, and Zfp36. CONCLUSIONS: These findings suggest that hyperoside exerts its osteogenic effects through migrasome-mediated crosstalk, offering new insights into the treatment of osteoporosis.

Fields of Study & Subjects

Bone Metabolism and Diseases Extracellular vesicles in disease Medicinal Plant Pharmacodynamics Research

Publication details

Journal / source
American Journal of Translational Research
Volume
18
Issue
3
Pages
1959–1971
Publication date
1 January 2026
Language
EN